---
title: "Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple Myeloma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300124141.md"
datetime: "2026-09-25T11:02:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300124141.md)
  - [en](https://longbridge.com/en/news/300124141.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300124141.md)
generator: "portal-rs"
---

# Single Infusion Of Carvykti Delivered Five-Year Treatment-Free Remissions In 50% Of Patients In Early Line Relapsed/Refractory Multiple Myeloma

Sept 25 (Reuters) - Johnson & Johnson (JNJ.N) : \* SINGLE INFUSION OF CARVYKTI® (CILTACABTAGENE AUTOLEUCEL) DELIVERED FIVE-YEAR TREATMENT-FREE REMISSIONS IN 50% OF PATIENTS IN EARLY LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA \* J&J - CARVYKTI DELIVERS FIVE-YEAR TREATMENT-FREE REMISSIONS IN 50% OF EARLY LINE RRMM PATIENTS \* J&J - FIVE-YEAR OVERALL SURVIVAL RATE 69.2%, MEDIAN PROGRESSION-FREE SURVIVAL 60.5 MONTHS Source text: Further company coverage: (JNJ.N)

### Related Stocks

- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [Trajan Wealth LLC Has $10.13 Million Stake in Johnson & Johnson $JNJ](https://longbridge.com/en/news/298127700.md)
- [Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition](https://longbridge.com/en/news/298947604.md)
- [The Fed's Preferred Inflation Metric Came in Cooler Than Expected. Here's What That Means for Interest Rates This Year](https://longbridge.com/en/news/300605428.md)
- [Nike Q1 Preview: Stock at 13-Year Lows, Market Expert Finds Bright Spot for Bulls](https://longbridge.com/en/news/300600878.md)
- [McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier](https://longbridge.com/en/news/300606178.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**